Register
FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder |
News and Updates
eMediNexus Coverage from: 
FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
eMediNexus,  10 October 2019
remove_red_eye 499 Views
#Dermatology #Internal Medicine #Pharmacist

0 Read Comments                

The U.S. Food and Drug Administration has granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.

Prior to this approval, there were no FDA-approved treatments to help erythropoietic protoporphyria patients increase their light exposure… (FDA, October 8, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now